Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.76
ESALY's Cash to Debt is ranked higher than
64% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ESALY: 0.76 )
ESALY' s 10-Year Cash to Debt Range
Min: 0.3   Max: No Debt
Current: 0.76

Equity to Asset 0.56
ESALY's Equity to Asset is ranked higher than
66% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ESALY: 0.56 )
ESALY' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.56
Current: 0.56

0.37
0.56
Interest Coverage 12.82
ESALY's Interest Coverage is ranked higher than
59% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. ESALY: 12.82 )
ESALY' s 10-Year Interest Coverage Range
Min: 10.54   Max: 2966.46
Current: 12.82

10.54
2966.46
F-Score: 5
Z-Score: 3.37
M-Score: -3.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.29
ESALY's Operating margin (%) is ranked higher than
75% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. ESALY: 9.29 )
ESALY' s 10-Year Operating margin (%) Range
Min: 2.42   Max: 16.84
Current: 9.29

2.42
16.84
Net-margin (%) 3.38
ESALY's Net-margin (%) is ranked higher than
67% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. ESALY: 3.38 )
ESALY' s 10-Year Net-margin (%) Range
Min: -2.32   Max: 10.55
Current: 3.38

-2.32
10.55
ROE (%) 3.83
ESALY's ROE (%) is ranked higher than
67% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. ESALY: 3.83 )
ESALY' s 10-Year ROE (%) Range
Min: -3.35   Max: 16.29
Current: 3.83

-3.35
16.29
ROA (%) 2.05
ESALY's ROA (%) is ranked higher than
69% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. ESALY: 2.05 )
ESALY' s 10-Year ROA (%) Range
Min: -1.78   Max: 9.17
Current: 2.05

-1.78
9.17
ROC (Joel Greenblatt) (%) 17.59
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. ESALY: 17.59 )
ESALY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.7   Max: 53.59
Current: 17.59

7.7
53.59
Revenue Growth (%) -7.90
ESALY's Revenue Growth (%) is ranked higher than
56% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ESALY: -7.90 )
ESALY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 11.9
Current: -7.9

0
11.9
EBITDA Growth (%) -11.40
ESALY's EBITDA Growth (%) is ranked higher than
59% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. ESALY: -11.40 )
ESALY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 45
Current: -11.4

0
45
EPS Growth (%) -21.20
ESALY's EPS Growth (%) is ranked higher than
60% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ESALY: -21.20 )
ESALY' s 10-Year EPS Growth (%) Range
Min: -21.2   Max: 53.8
Current: -21.2

-21.2
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 79.70
ESALY's P/E(ttm) is ranked higher than
70% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. ESALY: 79.70 )
ESALY' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 90.48
Current: 79.7

12.4
90.48
P/B 2.30
ESALY's P/B is ranked higher than
78% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. ESALY: 2.30 )
ESALY' s 10-Year P/B Range
Min: 1.74   Max: 2.73
Current: 2.3

1.74
2.73
P/S 2.10
ESALY's P/S is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. ESALY: 2.10 )
ESALY' s 10-Year P/S Range
Min: 0.96   Max: 6.6
Current: 2.1

0.96
6.6
PFCF 20.40
ESALY's PFCF is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ESALY: 20.40 )
ESALY' s 10-Year PFCF Range
Min: 5.75   Max: 50.18
Current: 20.4

5.75
50.18
EV-to-EBIT 24.66
ESALY's EV-to-EBIT is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. ESALY: 24.66 )
ESALY' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 53.7
Current: 24.66

9.2
53.7
Shiller P/E 25.40
ESALY's Shiller P/E is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. ESALY: 25.40 )
ESALY' s 10-Year Shiller P/E Range
Min: 15.93   Max: 28.84
Current: 25.4

15.93
28.84
Current Ratio 2.41
ESALY's Current Ratio is ranked higher than
71% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ESALY: 2.41 )
ESALY' s 10-Year Current Ratio Range
Min: 1.85   Max: 2.81
Current: 2.41

1.85
2.81
Quick Ratio 1.95
ESALY's Quick Ratio is ranked higher than
73% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ESALY: 1.95 )
ESALY' s 10-Year Quick Ratio Range
Min: 1.58   Max: 2.37
Current: 1.95

1.58
2.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.10
ESALY's Dividend Yield is ranked higher than
82% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. ESALY: 2.10 )
ESALY' s 10-Year Dividend Yield Range
Min: 2.02   Max: 5.11
Current: 2.1

2.02
5.11
Dividend Payout 1.77
ESALY's Dividend Payout is ranked higher than
66% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ESALY: 1.77 )
ESALY' s 10-Year Dividend Payout Range
Min: 0.85   Max: 888.89
Current: 1.77

0.85
888.89
Dividend growth (3y) -2.10
ESALY's Dividend growth (3y) is ranked higher than
72% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ESALY: -2.10 )
ESALY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 24.5
Current: -2.1

0
24.5
Yield on cost (5-Year) 1.78
ESALY's Yield on cost (5-Year) is ranked higher than
71% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. ESALY: 1.78 )
ESALY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8   Max: 4.55
Current: 1.78

1.8
4.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.59
ESALY's Price/Tangible Book is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. ESALY: 4.59 )
ESALY' s 10-Year Price/Tangible Book Range
Min: 4.15   Max: 16.81
Current: 4.59

4.15
16.81
Price/DCF (Projected) 1.16
ESALY's Price/DCF (Projected) is ranked higher than
93% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ESALY: 1.16 )
ESALY' s 10-Year Price/DCF (Projected) Range
Min: 0.71   Max: 1.17
Current: 1.16

0.71
1.17
Price/Median PS Value 1.45
ESALY's Price/Median PS Value is ranked higher than
64% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ESALY: 1.45 )
ESALY' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 3.82
Current: 1.45

0.68
3.82
Price/Graham Number 3.59
ESALY's Price/Graham Number is ranked higher than
75% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. ESALY: 3.59 )
ESALY' s 10-Year Price/Graham Number Range
Min: 1.83   Max: 3.79
Current: 3.59

1.83
3.79
Earnings Yield (Greenblatt) 4.10
ESALY's Earnings Yield (Greenblatt) is ranked higher than
81% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ESALY: 4.10 )
ESALY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 10.9
Current: 4.1

1.9
10.9
Forward Rate of Return (Yacktman) -2.71
ESALY's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. ESALY: -2.71 )
ESALY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.4   Max: 18.4
Current: -2.71

-3.4
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:4523.Japan, EII.Germany,
Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
AstraZeneca/Eli Lilly Start Mid-Stage Alzheimer's Study Dec 02 2014
Epizyme Gains on Positive Phase I Data on EPZ-6438 Nov 21 2014
Eisai Neuroscience Business Officially Launched in Belgium and Luxembourg Nov 09 2014
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance Nov 05 2014
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows Nov 04 2014
Lorcaserin Meets Primary Endpoint and Confirms Proof-Of-Concept as Potential Aid for Smoking... Nov 04 2014
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? Oct 31 2014
Eisai Announces Top-Line Results of Investigational Study on Coadministration of Lorcaserin and... Oct 28 2014
U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized... Oct 20 2014
U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib Oct 15 2014
U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients... Oct 15 2014
U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and... Oct 14 2014
Phase III Trial of Aricept in Patients with Severe Alzheimer's Disease in China Meets Primary... Sep 30 2014
Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies Sep 19 2014
Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate... Sep 18 2014
Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress Sep 17 2014
Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines Sep 16 2014
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. Aug 20 2014
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan Aug 18 2014
Eisai Supports Earthquake Relief Efforts in Yunnan, China Aug 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK